AMENDMENT TO THE CLAIMS

Please amend the claims as follows:

1-72. (canceled)

73. (new) A pharmaceutical composition comprising

i) one or more biodegradable hydrating ceramics

ii) one or more expandable agents,

iii) a sorbed aqueous medium, and

iv) one or more therapeutically, prophylactically and/or diagnostically active substances, which is an androgen or a derivative thereof, an anti-androgen or a derivative thereof, an oestrogen or a derivative thereof, an anti-oestrogen or a derivative thereof, a gestagen or a derivative thereof, an anti-gestagen or a derivative thereof, an oligonucleotide, a progestagen or a derivative thereof, a gonadotropin-releasing hormone or an analogeu or derivative thereof, a gonadotropin inhibitor or a derivative thereof, an adrenal and/or prostate enzyme inhibitor, a membrane efflux and/or membrane transport protein, an immune system modulator, an angiogenesis inhibitor, or combinations thereof,

which in solid form has a ruptured structure.

74. (new) A pharmaceutical composition according to claim 73, wherein the active substance is flutamide, hydroxy-flutamide, cyproteron, nilutamide or bicalutamide or a mixture thereof.

75. (new) A pharmaceutical composition according to claim 73, wherein the active substance is a combination of an anti-androgen and a gonadotropin-releasing hormone or an analogue thereof.

76. (new) A pharmaceutical composition according to claim 73, which in solid form has a

foam-like structure with openings, wherein at least 50% or more of the openings have a maximum width of at least about 0.1 mm.

77. (new) A pharmaceutical composition according to claim 76, wherein, at least 60%, to 90% of the openings have a maximum width of at least about 0.1 mm.

78. (new) A pharmaceutical composition according to claim 77, wherein the openings have a maximum width of at least about 0.2 mm to at least about 0.5 mm.

79. (new) A pharmaceutical composition according to claim 77, wherein the openings have a largest width of at least about 0.6 mm to about 2 mm.

80. (new) A pharmaceutical composition according to claim 73, wherein the surface area of an opening in cross sectional view having a maximum width of at least about 0.1 mm is at least about 3 $x10^{-8}$ m^2 to about 5 $x10^{-6}$ m^2.

81. (new) A pharmaceutical composition according to claim 73, which in solid form has a ruptured structure obtained by disintegration into two or more parts.

82. (new) A pharmaceutical composition according to claim 81, wherein the two or more parts have an external surface area that is at least about twice to about a thousand times as large as that of the composition before disintegration.

83. (new) A pharmaceutical composition according to claim 73, wherein the biodegradable hydrating ceramic is selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof.

84. (new) A pharmaceutical composition according to claim 73, wherein the biodegradable

hydrating ceramic is non-hydrated or hydrated calcium sulphate.

85. (new) A pharmaceutical composition according to claim 73, wherein the biodegradable hydrating ceramic employed in the preparation of the composition is in the form of a powder.

86. (new) A pharmaceutical composition according to claim 85, wherein the powder has a mean particle size of at the most about 10μm to about 75 μm.

87. (new) A pharmaceutical composition according to claim 73, wherein the expandable agent is a gas-forming agent, a swelling agent, a gelling agent or a disintegrant.

88. (new) A pharmaceutical composition according to claim 87, wherein the expandable agent is a gas-forming agent selected from the group consisting of alkali metal carbonates, alkali metal hydrogen carbonates, hydrogen peroxide and mixtures thereof.

89. (new) A pharmaceutical composition according to claim 87, wherein the expandable agent is a swelling agent, a gelling agent, a disintegrant, or mixtures thereof.

90. (new) A pharmaceutical composition according to claim 73, wherein the expandable agent is present in the composition at a concentration of at least about 0.1% w/w to about 10% w/w.

91. (new) A pharmaceutical composition according to claim 73, wherein the sorbed aqueous medium is present in the composition at a concentration of at the most about 30% w/w to about 60% w/w of the total composition.

92. (new) A pharmaceutical composition according to claim 73, in liquid, semi-solid or solid form.

93. (new) A pharmaceutical composition according to claim 92, in the form of a paste or another semi-solid form.

94. (new) A pharmaceutical composition according to claim 73, having a shape selected from the group consisting of beads, pellets, tubes, polygons, spheres, stars, cubes, or mixtures thereof.

95. (new) A pharmaceutical composition according to claim 73, wherein the active substance is homogeneously dispersed in the biodegradable hydrating ceramic.

96. (new) A pharmaceutical composition according to claim 73, configured for parenteral use.

97. (new) A pharmaceutical composition according to claim 73, wherein the one or more biodegradable hydrating ceramics, the expandable agent and the one or more active substance are homogeneously dispersed in water so that the hydrating ceramic, the expandable agent and/or the active substance sorbs water.

98. (new) A pharmaceutical composition according to claim 73, wherein the composition solidifies after a time period of about 20 min or less when stored at 37°C.

99. (new) A pharmaceutical composition according to claim 73, wherein the one or more biodegradable hydrating ceramics have a microporous structure.

100. (new) A pharmaceutical composition according to claim 99, wherein at least part of the microporous structures is sealed with a pore-sealing agent.

101. (new) A pharmaceutical composition according to claim 99, wherein at least 50% or more of the microporous structures is sealed with a pore-sealing agent.

102. (new) A pharmaceutical composition according to claim 100, wherein the pore-sealing agent is a hydrophobic agent, a hydrophilic agent, a water-absorbing agent, or mixtures thereof.

103. (new) A pharmaceutical composition according to claim 100, wherein the pore-sealing agent is a hydrophobic agent that is selected from the group consisting of silicone oil, silicon rubber, waxes, paraffinic hydrocarbons, polyvinylalcohols, ethyl cellulose, and mixtures thereof.

104. (new) A pharmaceutical composition according to claim 100, wherein the pore-sealing agent is a hydrophilic agent that is selected from the group consisting of methylcellulose, hyaluronic acid, dextran, poly-ethylene glycol (PEG), and mixtures thereof.

105. (new) A pharmaceutical composition according to claim 100, wherein the pore-sealing agent is a water- absorbing agent that is selected from the group consisting of water glasses, silica gel, sodium phosphate, and mixtures thereof.

106. (new) A pharmaceutical composition according to claim 100, wherein the concentration of the pore-sealing agent in the composition is about 30% w/w or less of the final composition.

107. (new) A pharmaceutical composition according to claim 73, wherein the active substance is controlled released from the composition.

108. (new) A pharmaceutical composition according to claim 107, wherein at most about 10% w/w of the active substance contained in the composition is released 5 days or more after implantation to a human.

109. (new) A pharmaceutical composition according to claim 107, wherein at the most about 50% w/w of the active substance contained in the composition is released 1 month or more after implantation to a human.

110. (new) A pharmaceutical composition according to claim 107, wherein at the most about 75% w/w of the active substance contained in the composition is released 1.5 month or more after implantation to a human.

111. (new) A pharmaceutical composition according to claim 107, wherein at the most about

100% w/w of the active substance contained in the composition is released 2 month or more after implantation to a human.

112. (new) A pharmaceutical composition according to claim 107, wherein at the most about 10% w/w of the active substance contained in the composition is released after 2 days or more when tested in an *in vitro* dissolution test according to Ph. Eur protocol.

113. (new) A pharmaceutical composition according to claim 107, wherein at the most about 50% w/w of the active substance contained in the composition is released after 1 month or more when tested in an *in vitro* dissolution test according to Ph. Eur protocol.

114. (new) A pharmaceutical composition according to claim 107, wherein at the most about 75% w/w of the active substance contained in the composition is released after 1.5 month or more when tested in an *in vitro* dissolution test according to Ph. Eur protocol.

115. (new) A pharmaceutical composition according to claim 107, wherein at the most about 100% w/w of the active substance contained in the composition is released after 2 month or more when tested in an in vitro dissolution test according to Ph. Eur protocol.

116. (new) A composition in particulate form for use in the preparation of a pharmaceutical composition as recited in claim 73, the composition comprising:

i) one or more biodegradable hydrating ceramics in powder form

ii) one or more expandable agents, and

iii) optionally, one or more therapeutically, prophylactically and/or diagnostically active substances, which is an androgen or a derivative thereof, an anti-androgen or a derivative thereof, an oestrogen or a derivative thereof, an anti-oestrogen or a derivative thereof, a gestagen or a derivative thereof, an anti-gestagen or a derivative thereof, an oligonucleotide, a progestagen or a derivative thereof, a gonadotropin-releasing hormone or an analogeu or derivative thereof, a gonadotropin inhibitor or a derivative thereof, an adrenal and/or prostate enzyme inhibitor, a membrane efflux and/or membrane transport protein, an immune system modulator, an angiogenesis inhibitor, or combinations thereof.

.

117. (new) A method for the preparation of a pharmaceutical composition as recited in claim 73, comprising dispersing a mixture of: i) one or more biodegradable hydrating ceramics in powder form, and ii) one or more expandable agents, in iii) an aqueous medium, wherein either the mixture of i) and ii), or iii) further comprises iv) one or more therapeutically, prophylactically and/or diagnostically active substances, which is an androgen or a derivative thereof, an anti-androgen or a derivative thereof, an oestrogen or a derivative thereof, an anti-oestrogen or a derivative thereof, a gestagen or a derivative thereof, an anti-gestagen or a derivative thereof, an oligonucleotide, a progestagen or a derivative thereof, a gonadotropin-releasing hormone or an analogeu or derivative thereof, a gonadotropin inhibitor or a derivative thereof, an adrenal and/or prostate enzyme inhibitor, a membrane efflux and/or membrane transport protein, an immune system modulator, an angiogenesis inhibitor, or combinations thereof.

118. (new) A method according to claim 117, wherein the pharmaceutical composition is an injectable and *in vivo* solidifying composition for controlled release of the active substance.

119. (new) A method for treatment of a subject suffering from a prostate disease, comprising administering to the subject a composition comprising:

i) one or more biodegradable hydrating ceramics

ii) one or more expandable agents,

iii) sorbed aqueous medium, and

iv) one or more therapeutically, prophylactically and/or diagnostically active substances, which is an androgen or a derivative thereof, an anti-androgen or a derivative thereof, an oestrogen or a derivative thereof, an anti-oestrogen or a derivative thereof, a gestagen or a derivative thereof, an anti-gestagen or a derivative thereof, an oligonucleotide, a progestagen or a derivative thereof, a gonadotropin-releasing hormone or an analog or derivative thereof, a gonadotropin inhibitor or a derivative thereof, an adrenal and/or prostate enzyme inhibitor, a membrane efflux and/or membrane transport protein, an immune system modulator, an angiogenesis inhibitor, or combinations thereof.

120. (new) A method according to claim 119, wherein the prostate disease is prostate cancer or prostate hyperplasia.

130. (new) A method according to claim 119, wherein the active substance is flutamide, hydroxy-flutamide, cyproteron, nilutamide or bicalutamide or a mixture thereof.

140. (new) A method according to claim 119, wherein the active substance is a combination of an anti-androgen and a gonadotropin-releasing hormone or an analog thereof.

141. (new) A method according to claim 119, wherein the active substance is hydroxyflutamide.

142. (new) A method according to claim 119, wherein the active substance is hydroxyflutamide and a plasma concentration of from 0.001 to 1000 μM hydroxyflutamide is obtained in the subject after administration thereof.

143. (new) A method according to claim 119, wherein the active substance is hydroxyflutamide and the treatment time for one dose is at least 3-6 months.

144. (new) A method according to claim 119, wherein the composition is administered to a subject's prostate tissue by implantation.

145. (new) A method according to claim 119, wherein the composition is injectable and solidifies *in vivo* after administration.